FDA Approves Pembrolizumab for Stage 3/4a Cervical Cancer FDA Approves Pembrolizumab for Stage 3/4a Cervical Cancer

The new approval marks the 40th oncology indication for pembrolizumab across 19 cancer types, including two previous metastatic cervical cancer approvals.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news